KZR

Kezar Life Sciences, Inc. KZR

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 46 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-5.76M

Quarter to Mar 31

Free cash flow

$-7.45M

Quarter to Mar 31

Top Institutional Holders

as of Q1 2026
$32.83M total
BML Capital Management, LLC
$5.35M0.0%
SUVRETTA CAPITAL MANAGEMENT, LLC
$5.32M0.0%
TANG CAPITAL MANAGEMENT LLC
$4.93M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$2.16M--
Rangeley Capital, LLC
$1.80M+182.9%
Affinity Asset Advisors, LLC
$1.70M0.0%
RENAISSANCE TECHNOLOGIES LLC
$1.40M+43.5%
ACADIAN ASSET MANAGEMENT LLC
$1.12M+20.9%
MILLENNIUM MANAGEMENT LLC
$1.05MNew
Peapod Lane Capital LLC
$924.5K0.0%
Ikarian Capital, LLC
$758.4K0.0%
BlackRock, Inc.
$742.5K+1.4%
ADAR1 Capital Management, LLC
$607.9K-65.1%
Groupe la Francaise
$596.6KNew
Aldebaran Capital, LLC
$596.1K-0.4%
GEODE CAPITAL MANAGEMENT, LLC
$452.6K-10.5%
CITADEL ADVISORS LLC
$440.8KNew
CREDIT INDUSTRIEL ET COMMERCIAL
$397.7KNew
TORNO CAPITAL, LLC
$359.7K+142.4%
VANGUARD FIDUCIARY TRUST CO
$305.7K--
DIMENSIONAL FUND ADVISORS LP
$225.1K+14.3%
RBF Capital, LLC
$208.8K-50.0%
STATE STREET CORP
$201.0K0.0%
Yakira Capital Management, Inc.
$178.1KNew
Vazirani Asset Management LLC
$163.2K-54.6%
See all 42 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q1 2026
EDGAR

EPS (Diluted)

Q1 2026
EDGAR

ROIC

Q1 2026
EDGAR

Free Cash Flow

Q1 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/KZR

Earnings Per Share

13fpro.ai/company/KZR

Loading ratio trend…

About Kezar Life Sciences, Inc. (KZR): stock profile, AI score and financials

Kezar Life Sciences, Inc. (KZR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. KZR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 46 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Kezar Life Sciences, Inc. reports net income of $-5.8M, free cash flow of $-7.4M. KZR trades on the Nasdaq exchange and files with the SEC under CIK 1645666. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KZR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kezar Life Sciences, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1645666 →